一种新的分级方法可预测pT1期非肌层浸润性膀胱癌的更差结局
该研究回顾性分析113例接受经尿道膀胱肿瘤电切术的pT1期非肌层浸润性膀胱癌患者的组织标本与临床数据,基于肿瘤出芽、生长模式和浸润模式建立分级系统。由两种肿瘤出芽分组、两种生长模式和两种浸润模式整合得出的不利分级组(n=28,24.7%)为无复发生存和总生存的独立预测因素,并与更差的无进展生存和癌症特异性生存相关。
要点
- 基于肿瘤出芽、生长模式和浸润模式整合的不利分级组占24.7%(28/113),对肿瘤学结局影响大。
- 不利分级组是无复发生存(P=0.004)和总生存(P=0.046)的独立预测因素。
- 不利分级组与更差的无进展生存(P=0.001)和癌症特异性生存(P=0.001)相关,且与更高的卡介苗无应答肿瘤率相关(P=0.006)。
核心结论
- 作者提出一种基于形态学的pT1期非肌层浸润性膀胱癌分级系统,与疾病侵袭性和肿瘤学患者结局相关,可识别最高风险组患者。
- 作者认为最高风险组患者应更密切随访或立即接受根治性膀胱切除术。
- 该分级纳入可在苏木精-伊红染色切片和免疫组化上评估的客观变量,是一种易于使用、低成本且适用于日常常规的方法。
- 需要进一步研究来验证和确认这些结果。
研究设计与样本
- 回顾性研究,纳入113例接受经尿道膀胱肿瘤电切术的pT1期非肌层浸润性膀胱癌患者的组织标本和临床数据。
- 评估肿瘤出芽、生长模式和浸润模式并分类为两个分级组(GGs)。
- 采用单变量和多变量Cox回归分析探讨分级组及其他临床和病理组织学变量与无复发生存、无进展生存、癌症特异性生存和总生存的关系。
主要发现
- 由两种肿瘤出芽分组、两种生长模式和两种浸润模式整合得出不利分级组(n=28;24.7%),对肿瘤学结局影响大。
- 不利分级组是无复发生存(P=0.004)和总生存(P=0.046)的独立预测因素。
- 不利分级组与更差的无进展生存(P=0.001)和癌症特异性生存(P=0.001)相关,不受欧洲泌尿外科学会风险分组影响。
- 不利分级组与更高的卡介苗无应答肿瘤率相关(P=0.006)。
临床怎么用
- 作者认为该分级系统可识别pT1期非肌层浸润性膀胱癌的最高风险组患者,这些患者应更密切随访或立即接受根治性膀胱切除术。
- 该分级纳入可在苏木精-伊红染色切片和免疫组化上评估的客观变量,作者认为其易于使用、低成本且适用于日常常规。
局限性
- 研究局限性包括回顾性设计。
- 研究局限性包括单中心设计。
- 研究局限性包括治疗方式多样。
- 研究局限性包括队列小。
- 需要进一步研究来验证和确认这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop a prognostically relevant scoring system for stage pT1 non-muscle-invasive bladder cancer (NMIBC) incorporating tumour budding, growth pattern and invasion pattern because the World Health Organisation grading system shows limited prognostic value in such patients. PATIENTS AND METHODS: The tissue specimens and clinical data of 113 patients with stage pT1 NMIBC who underwent transurethral resection of bladder tumour were retrospectively investigated. Tumour budding, and growth and invasion patterns were evaluated and categorised into two grade groups (GGs). GGs and other clinical and histopathological variables were investigated regarding recurrence-free survival (RFS), progression-free survival (PFS), cancer-specific survival (CSS) and overall survival (OS) using univariable and multivariable Cox regression analyses. RESULTS: The integration of two tumour budding groups, two growth patterns, and two invasion patterns yielded an unfavourable GG (n = 28; 24.7%) that had a high impact on oncological outcomes. The unfavourable GG was identified as an independent RFS and OS predictor (P = 0.004 and P = 0.046, respectively) and linked to worse PFS (P = 0.001) and CSS (P = 0.001), irrespective of the European Association of Urology risk group. The unfavourable GG was associated with higher rates of BCG-unresponsive tumours (P = 0.006). Study limitations include the retrospective, single-centre design, diverse therapies and small cohort. CONCLUSIONS: We present a morphology-based grading system for stage pT1 NMIBC that correlates with disease aggressiveness and oncological patient outcomes. It therefore identifies a highest risk group of stage pT1 NMIBC patients, who should be followed up more intensively or receive immediate radical cystectomy. The grading incorporates objective variables assessable on haematoxylin and eosin slides and immunohistochemistry, enabling an easy-to-use low-cost approach that is applicable in daily routine. Further studies are needed to validate and confirm these results.
引用
- Haas M, Engelmann SU, Mayr R, et al. A novel grading approach predicts worse outcomes in stage pT1 non-muscle-invasive bladder cancer. BJU Int. 2024. PMID: 38409965. doi:10.1111/bju.16298
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。